Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.

Nature communications - 28 Nov 2023

Ji Yiyi, Zhang Weiwei, Shen Kai, Su Ruopeng, Liu Xinyu, Ma Zehua, Liu Bo, Hu Cong, Xue Yizheng, Xin Zhixiang, Yang Yi, Li Ang, Jiang Zhou, Jing Na, Zhu Helen He, Dong Liang, Zhu Yinjie, Dong Baijun, Pan Jiahua, Wang Qi, Xue Wei

Abstract excerpt

Neuroendocrine prostate cancer is a rapidly progressive and lethal disease characterized by early visceral metastasis, poor prognosis, and limited treatment options. Uncovering the oncogenic mechanisms could lead to the discovery of potential therapeutic avenues. Here, we demonstrate that the RNA-binding protein ELAVL3 is specifically upregulated in neuroendocrine prostate cancer and that overexpression of ELAVL3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feedback

Share to MYCN gene

Share to N-Myc Proto-Oncogene Protein

Share to Phenotype

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38016952
DOI: 10.1038/s41467-023-43676-3
PMCID: PMC10684895

Genes

ELAVL3
MYCN
RICTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.PMID 38016952Read ↗

The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanismsSemantic proximity Read ↗

BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2Semantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Semantic proximity Read ↗

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancerSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Semantic proximity Read ↗

A novel REST-regulated lncRNA PCAT-NE1 induces neuroendocrine differentiation in castration-resistant prostate cancerSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 ExpressionSemantic proximity Read ↗

RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate CancerSemantic proximity Read ↗

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read ↗

A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene networkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.